Le Lézard
Classified in: Health, Science and technology, Business
Subject: PER

George Mashini Joins Welsh, Carson, Anderson & Stowe as An Operating Partner in the Firm's Technology Group


NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the technology and healthcare industries, announced today that George Mashini has joined the firm as an Operating Partner.

Mr. Mashini has over 15 years of technology leadership experience. Most recently, he was Chief Revenue Officer and Chief Technology Officer at Quick Base, a WCAS portfolio company offering a leading low-code development platform. As Chief Revenue Officer at Quick Base, he led a complete transformation of the company's go to market program including rebuilding the sales team, which resulted in a significant increase in bookings and more than doubling in the number of enterprise accounts. While serving as Chief Technology Officer, he revamped Quick Base's cloud platform, which drove strong expansion in enterprise adoption.

Prior to Quick Base, Mr. Mashini served as President of Hexagon AB's platforms division, where he primarily focused on the development of IoT technologies and the global go to market of those technologies across several industries. He was also Chief Executive Officer of Catavolt, Inc., a global provider of enterprise mobility solutions, which he successfully scaled and sold to Hexagon AB.  

Mike Donovan, WCAS General Partner, said: "We have worked with George for many years at Quick Base. We are pleased that he is now joining WCAS given his deep experience in enterprise software. He will work closely with our Technology team to evaluate potential investments and partner with our portfolio companies to maximize value creation."

George Mashini added, "I have partnered with WCAS for several years while working at Quick Base and I am excited to join the team given the firm's long and successful track record of building world class technology and healthcare companies."

Over the past four decades, WCAS has successfully invested over $11 billion of equity in 105 technology companies through its 13 private equity funds.

About Welsh, Carson, Anderson & Stowe

WCAS is a leading U.S. private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. The firm has raised and managed funds totaling over $27 billion of committed capital. For more information, please visit www.wcas.com.

Contacts:

Jon Rather
212-893-9570
[email protected]  

Greg Lau
212-893-9586
[email protected]

 

SOURCE Welsh, Carson, Anderson & Stowe


These press releases may also interest you

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....



News published on and distributed by: